|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for SERPINE2 |
 Gene summary |
| Basic gene Info. | Gene symbol | SERPINE2 |
| Gene name | serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 | |
| Synonyms | GDN|GDNPF|PI-7|PI7|PN-1|PN1|PNI | |
| Cytomap | UCSC genome browser: 2q36.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001136528.1, NM_001136530.1,NM_006216.3,NR_073116.1, | |
| Description | glia-derived nexinglial-derived neurite promoting factorpeptidase inhibitor 7protease nexin Iserpin E2 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 177010 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000135919 | ||
| HPRD : 01510 | ||
| Vega : OTTHUMG00000133163 | ||
| Protein | UniProt: P07093 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_SERPINE2 | |
| BioGPS: 5270 | ||
| Pathway | NCI Pathway Interaction Database: SERPINE2 | |
| KEGG: SERPINE2 | ||
| REACTOME: SERPINE2 | ||
| Pathway Commons: SERPINE2 | ||
| Context | iHOP: SERPINE2 | |
| ligand binding site mutation search in PubMed: SERPINE2 | ||
| UCL Cancer Institute: SERPINE2 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0030195 | negative regulation of blood coagulation | 17379830 | GO:0045861 | negative regulation of proteolysis | 17379830 | GO:0048711 | positive regulation of astrocyte differentiation | 1691280 |
| Top |
| Ligand binding site mutations for SERPINE2 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | T328 | I327M | BRCA | 1 | E123 | P125H | COAD | 1 | T328 | I327T | LUAD | 1 | G330 | G330E | OV | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for SERPINE2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | E123 | P125H | -0.93567561 | T328 | I327T | -0.86266693 | T328 | I327M | -0.66430995 | G330 | G330E | -0.22411669 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for SERPINE2 from PDB |
| Top |
| Differential gene expression and gene-gene network for SERPINE2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for SERPINE2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for SERPINE2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of SERPINE2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of SERPINE2 |
| Multiple alignments for P07093 in multiple species |
| LBS | AA sequence | # species | Species | A325 | SKANFAKITTG | 1 | Homo sapiens | A325 | SKANFTKITR- | 1 | Mus musculus | A325 | SKANFAKITR- | 1 | Rattus norvegicus | E123 | NASEIEVPFVT | 1 | Homo sapiens | E123 | NGFKMEVPFAV | 1 | Mus musculus | E123 | NGFKVEVPFAA | 1 | Rattus norvegicus | G330 | AKITTGSENLH | 1 | Homo sapiens | G330 | TKITR-SESLH | 1 | Mus musculus | G330 | AKITR-SESLH | 1 | Rattus norvegicus | T328 | NFAKITTGSEN | 1 | Homo sapiens | T328 | NFTKITR-SES | 1 | Mus musculus | T328 | NFAKITR-SES | 1 | Rattus norvegicus | T329 | FAKITTGSENL | 1 | Homo sapiens | T329 | FTKITR-SESL | 1 | Mus musculus | T329 | FAKITR-SESL | 1 | Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |